{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T02:35:39Z","timestamp":1783391739823,"version":"3.54.6"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s12282-025-01680-z","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T13:28:37Z","timestamp":1739194117000},"page":"607-612","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A prospective cohort study of abemaciclib-induced interstitial lung disease in metastatic breast cancer after chemotherapy"],"prefix":"10.1007","volume":"32","author":[{"given":"Sayuka","family":"Nakayama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5835-5160","authenticated-orcid":false,"given":"Takayuki","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Araki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Narui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nagase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naruto","family":"Taira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Aihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Kikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Mukai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"issue":"12","key":"1680_CR1","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","volume":"31","author":"F Cardoso","year":"2020","unstructured":"Cardoso F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623\u201349.","journal-title":"Ann Oncol"},{"issue":"25","key":"1680_CR2","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","volume":"35","author":"GW Sledge Jr","year":"2017","unstructured":"Sledge GW Jr, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with hr+\/her2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875\u201384.","journal-title":"J Clin Oncol"},{"issue":"32","key":"1680_CR3","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz MP, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638\u201346.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1680_CR4","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1002\/onco.13531","volume":"26","author":"HS Rugo","year":"2021","unstructured":"Rugo HS, et al. Management of abemaciclib-associated adverse events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: safety analysis of MONARCH 2 and MONARCH 3. Oncologist. 2021;26(1):e53\u201365.","journal-title":"Oncologist"},{"issue":"3","key":"1680_CR5","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1007\/s12282-020-01207-8","volume":"28","author":"Y Chen","year":"2021","unstructured":"Chen Y, et al. Characteristics of interstitial lung disease in patients from post-marketing data on metastatic breast cancer patients who received abemaciclib in Japan. Breast Cancer. 2021;28(3):710\u20139.","journal-title":"Breast Cancer"},{"issue":"4","key":"1680_CR6","doi-asserted-by":"publisher","first-page":"216","DOI":"10.14740\/wjon1511","volume":"13","author":"K Miyahara","year":"2022","unstructured":"Miyahara K, et al. Prospective cohort study of combination therapy with abemaciclib and hormonal therapy for chemotherapy-treated patients with hormone receptor-positive metastatic breast cancer. World J Oncol. 2022;13(4):216\u201321.","journal-title":"World J Oncol"},{"issue":"4","key":"1680_CR7","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.resinv.2013.09.001","volume":"51","author":"K Kubo","year":"2013","unstructured":"Kubo K, et al. Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir Investig. 2013;51(4):260\u201377.","journal-title":"Respir Investig"},{"issue":"10","key":"1680_CR8","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3390\/jcm7100356","volume":"7","author":"S Skeoch","year":"2018","unstructured":"Skeoch S, et al. Drug-induced interstitial lung disease: a systematic review. J Clin Med. 2018;7(10):356.","journal-title":"J Clin Med"},{"issue":"1","key":"1680_CR9","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12957-021-02289-0","volume":"19","author":"K Tezuka","year":"2021","unstructured":"Tezuka K, et al. Interstitial lung disease associated with adjuvant and neoadjuvant chemotherapy in early breast cancer. World J Surg Oncol. 2021;19(1):169.","journal-title":"World J Surg Oncol"},{"issue":"1","key":"1680_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10549-020-05754-8","volume":"183","author":"MD Hackshaw","year":"2020","unstructured":"Hackshaw MD, et al. Incidence of pneumonitis\/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2020;183(1):23\u201339.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"1680_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100404","volume":"7","author":"P Conte","year":"2022","unstructured":"Conte P, et al. Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment. ESMO Open. 2022;7(2): 100404.","journal-title":"ESMO Open"},{"issue":"4","key":"1680_CR12","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.rmed.2012.01.002","volume":"106","author":"JJ Swigris","year":"2012","unstructured":"Swigris JJ, et al. Ethnic and racial differences in the presence of idiopathic pulmonary fibrosis at death. Respir Med. 2012;106(4):588\u201393.","journal-title":"Respir Med"},{"issue":"16","key":"1680_CR13","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1056\/NEJMoa1013660","volume":"364","author":"MA Seibold","year":"2011","unstructured":"Seibold MA, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med. 2011;364(16):1503\u201312.","journal-title":"N Engl J Med"},{"issue":"11","key":"1680_CR14","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s40264-020-00968-7","volume":"43","author":"E Iwasa","year":"2020","unstructured":"Iwasa E, et al. Interstitial lung disease as an adverse drug reaction in japan: exploration of regulatory actions as a basis for high reporting. Drug Saf. 2020;43(11):1121\u201331.","journal-title":"Drug Saf"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-025-01680-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-025-01680-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-025-01680-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T09:41:10Z","timestamp":1744450870000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-025-01680-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1680"],"URL":"https:\/\/doi.org\/10.1007\/s12282-025-01680-z","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,10]]},"assertion":[{"value":"7 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TN has received lecture fees from Eli Lilly, Chugai Pharmaceuticals Co. AstraZeneca, Pfizer, Daiichi-Sankyo, Eisai, Novartis, MSD, Sandoz, Yakult and Nippon Kayaku. NT has received lecture fee from Eli Lilly. His institution has received research support from Eli Lilly. YK has received lecture fees from Eli Lilly, Eisai, Pfizer, Chugai Pharmaceuticals Co., Ltd., Daiichi-Sankyo and AstraZeneca. HM has received lecture fee from Taiho Pharmaceutical and Takeda Pharmaceutical. All remaining authors have declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study protocol and all amendments received approval from the Research Ethics Committee of Gunma Prefectural Cancer Center, Japan (Date: December 4, 2019\/ No.405-31063).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}